Editas Medicine, Inc.

NasdaqGS:EDIT Voorraadrapport

Marktkapitalisatie: US$239.3m

Editas Medicine Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Editas Medicine heeft een totaal eigen vermogen van $232.0M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $384.8M en $152.8M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$279.11m
AandelenUS$232.01m
Totaal verplichtingenUS$152.79m
Totaal activaUS$384.80m

Recente financiële gezondheidsupdates

Recent updates

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25
Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $286.4M ) EDIT } overtreffen de korte termijn passiva ( $74.3M ).

Langlopende schulden: De kortetermijnactiva EDIT ( $286.4M ) overtreffen de langetermijnschulden ( $78.5M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: EDIT is schuldenvrij.

Schuld verminderen: EDIT had 5 jaar geleden geen schulden.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: EDIT heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: EDIT heeft voldoende kasruimte voor 1 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 15.8 % per jaar.


Ontdek gezonde bedrijven